(2R,3S,4R,5R)-2,3,4,5-四羟基-6-甲氧基己醛 | 2461-70-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2R,3S,4R,5R)-2,3,4,5-四羟基-6-甲氧基己醛
• 英文名称: 6-O-methyl-D-glucose
• 英文别名: 6-O-methyl-Δ-glucose；O⁶-methyl-D-glucose；2,3,5,6-Tetrahydroxy-6-methoxy-D-gluco-hexanal；O⁶-Methyl-D-glucose；6-Methyl-glucose；6-O-Methylglucose；(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-methoxyhexanal
• CAS: 2461-70-3
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: GFHNQKKLOLZRQE-BDVNFPICSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  456.9±45.0 °C(Predicted)
• 密度：
  1.394±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,3S,4R,5R)-2,3,4,5-四羟基-6-甲氧基己醛 在 乙醇 、 sodium ethanolate 、 zinc(II) chloride 作用下， 生成 (4-nitro-phenyl)-(O⁶-methyl-β-D-glucopyranoside)
  参考文献：
  名称：

  Jermyn, Australian Journal of Chemistry, 1957, vol. 10, p. 448,450

  摘要：

  DOI：
• 作为产物：
  描述：

  3,5-O-苄叉-1,2-O-异丙叉-alpha-D呋喃葡萄糖 在 硫酸 、 barium(II) oxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (2R,3S,4R,5R)-2,3,4,5-四羟基-6-甲氧基己醛
  参考文献：
  名称：

  Bock; Meldal; Meyer, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1983, vol. 37, # 2, p. 101 - 108

  摘要：

  DOI：

文献信息

• Process for producing saccharide fatty acid monoesters
  申请人：LION CORPORATION

  公开号：EP0413307A1

  公开（公告）日：1991-02-20

  A process for producing a saccharide fatty acid monoester comprises reacting an immobilized thermostable lipase on a mixture comprising: (A) one or more of acyl donors selected from saturated and unsaturated fatty acids with 6 to 22 carbon atoms, lower alkyl esters of said fatty acids and glycerol esters of said fatty acids, (B) one or more of saccharides selected from monosaccharides with 5 to 7 carbon atoms, disaccharides composed of hexose, sugar alcohols with 4 to 6 carbon atoms, ethers of monosaccharides with 5 to 7 carbon atoms and monohydric alcohols and ethers of disaccharides composed of hexose and monohydric alcohols, and (C) one or more of alcohols selected from secondary alcohols and tertiary alcohols.

  一种生产糖类脂肪酸单酯的工艺包括将固定化的恒温脂肪酶与一种混合物反应，该混合物包括 (A) 一种或多种选自具有 6 至 22 个碳原子的饱和和不饱和脂肪酸、所述脂肪酸的低级烷基酯和所述脂肪酸的甘油酯的酰基供体、 (B) 一种或多种选自 5 至 7 个碳原子的单糖、由己糖组成的二糖、4 至 6 个碳原子的糖醇、5 至 7 个碳原子的单糖和一元醇的醚以及由己糖和一元醇组成的二糖的醚的糖类，以及 (C) 选自仲醇和叔醇的一种或多种醇。
• Process for preparing fatty acid esters of saccharides
  申请人：LION CORPORATION

  公开号：EP0507323A2

  公开（公告）日：1992-10-07

  A process for preparing fatty acid esters of saccharides which comprises subjecting at least one saccharide selected from monosaccharides having from 5 to 7 carbon atoms, disaccharides consisting of hexoses, sugar alcohols having from 4 to 6 carbon atoms, ether compounds consisting of monosaccharides having from 5 to 7 carbon atoms and monohydric alcohols, and ether compounds consisting of hexose disaccharides and monohydric alcohols, to reaction with at least one member selected from saturated and unsaturated fatty acids having from 6 to 22 carbon atoms and esters of the above-defined fatty acids and lower alcohols in the presence of an organic solvent by the use of a hydrolase. The organic solvent is at least one member selected from the group consisting of acetylacetone, ethylene carbonate, propylene carbonate, y-butyrolactone and heterocyclic compounds of the following general formula (1) wherein R represents a linear or branched alkyl group having from 1 to 3 carbon atoms.

  一种制备糖类脂肪酸酯的工艺，包括将至少一种选自具有 5 至 7 个碳原子的单糖、由己糖组成的二糖、具有 4 至 6 个碳原子的糖醇、由具有 5 至 7 个碳原子的单糖和一元醇组成的醚化合物以及由己糖二糖和一元醇组成的醚化合物的糖类与至少一种选自具有 6 至 22 个碳原子的饱和及不饱和脂肪酸的酯反应、以及由六糖二糖和一元醇组成的醚类化合物，在有机溶剂存在下，通过使用水解酶，与至少一种选自具有 6 至 22 个碳原子的饱和及不饱和脂肪酸以及上述脂肪酸和低级醇的酯类化合物发生反应。有机溶剂至少是选自乙酰丙酮、碳酸乙烯酯、碳酸丙烯酯、丁内酯和以下通式 (1) 的杂环化合物组成的组中的一个成员 其中 R 代表具有 1 至 3 个碳原子的直链或支链烷基。
• Reprogramming of cells to a new fate
  申请人：The Scripps Research Institute

  公开号：US10308912B2

  公开（公告）日：2019-06-04

  The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

  本发明一般提供动物细胞从第一种非全能细胞命运向第二种非全能细胞命运转分化的方法和组合物。本发明还提供了将动物细胞从非多能中胚层、内胚层或外胚层细胞命运转分化为不同的非多能中胚层、内胚层或外胚层细胞命运的方法和组合物。
• Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
  申请人：Propanc Pty Ltd

  公开号：US10350239B2

  公开（公告）日：2019-07-16

  The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.

  本发明一般涉及含有蛋白酶原的药物组合物及其治疗癌症的用途。这些药物组合物涉及包含蛋白酶原和活性剂的组合物，该组合物能够提供治疗癌症的多功能方法。本发明的药物组合物还涉及包含第一和第二蛋白酶原的组合物，第一和第二蛋白酶原能够在肿瘤细胞表面或其附近活化，以增强肿瘤细胞的细胞间粘附性，影响肿瘤细胞的蛋白分解，或诱导肿瘤细胞凋亡、分化或免疫认知，其中第一蛋白酶原是糜蛋白酶原，第二蛋白酶原是胰蛋白酶原。该药物组合物还涉及包含第一和第二活性剂的组合物，每种活性剂都能诱导肿瘤细胞的细胞内活性。
• Biosynthesis of everninomicin analogs in Micromonospora carbonacea var aurantiaca
  申请人：VANDERBILT UNIVERSITY

  公开号：US10696996B2

  公开（公告）日：2020-06-30

  Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclosed.

  本发明公开了通过改变小孢子虫（Micromonospora carbonacea）的基因来制备 Everninomicin 类似物的方法。还公开了通过这些方法制备的常新霉素类似物以及使用这些类似物治疗感染的方法。